메뉴 건너뛰기




Volumn 25, Issue 4, 2015, Pages 534-539

Efficacy at 52 weeks of daily clinical use of iguratimod in patients with rheumatoid arthritis

Author keywords

Disease modifying antirheumatic drugs; Iguratimod; Matrix metalloproteinase 3; Methotrexate; Rheumatoid arthritis

Indexed keywords

ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; IGURATIMOD; METHOTREXATE; STROMELYSIN; WARFARIN; CHROMONE DERIVATIVE; SULFONAMIDE;

EID: 84934893887     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.998361     Document Type: Article
Times cited : (25)

References (34)
  • 2
    • 84924836256 scopus 로고    scopus 로고
    • Cost-eff ectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis
    • Wailoo A, Hernández MA, Scott IC, Ibrahim F, Scott DL. Cost-eff ectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis. Rheumatology (Oxford). 2014;53(10): 1773–7.
    • (2014) Rheumatology (Oxford) , vol.53 , Issue.10 , pp. 1773-1777
    • Wailoo, A.1    Hernández, M.A.2    Scott, I.C.3    Ibrahim, F.4    Scott, D.L.5
  • 3
    • 84860511740 scopus 로고    scopus 로고
    • Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial
    • van Vollenhoven RF, Geborek P, Forslind K, Albertsson K, Ernestam S, Petersson IF, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet. 2012;379(9827):1712–20.
    • (2012) Lancet , vol.379 , Issue.9827 , pp. 1712-1720
    • Van Vollenhoven, R.F.1    Geborek, P.2    Forslind, K.3    Albertsson, K.4    Ernestam, S.5    Petersson, I.F.6
  • 4
    • 77953696525 scopus 로고    scopus 로고
    • EULAR recommendations forthe management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    • Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations forthe management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010;69(6):964–75.
    • (2010) Ann Rheum Dis , vol.69 , Issue.6 , pp. 964-975
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Dougados, M.4    Emery, P.5    Gaujoux-Viala, C.6
  • 5
    • 84893772728 scopus 로고    scopus 로고
    • EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
    • Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014; 73(3): 492–509.
    • (2014) Ann Rheum Dis , vol.73 , Issue.3 , pp. 492-509
    • Smolen, J.S.1    Landewé, R.2    Breedveld, F.C.3    Buch, M.4    Burmester, G.5    Dougados, M.6
  • 6
    • 79958860140 scopus 로고    scopus 로고
    • Lefl unomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury
    • Inokuma S. Lefl unomide-induced interstitial pneumonitis might be a representative of disease-modifying antirheumatic drug-induced lung injury. Expert Opin Drug Saf. 2011;10(4):603–11.
    • (2011) Expert Opin Drug Saf , vol.10 , Issue.4 , pp. 603-611
    • Inokuma, S.1
  • 7
    • 70350755699 scopus 로고    scopus 로고
    • Factors associated with fatal outcome of lefl unomide-induced lung injury in Japanese patients with rheumatoid arthritis
    • Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, et al. Factors associated with fatal outcome of lefl unomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1265–8.
    • (2009) Rheumatology (Oxford) , vol.48 , Issue.10 , pp. 1265-1268
    • Sato, T.1    Inokuma, S.2    Sagawa, A.3    Matsuda, T.4    Takemura, T.5    Otsuka, T.6
  • 8
    • 70349785354 scopus 로고    scopus 로고
    • Lefl unomide-induced interstitial lung disease:Prevalence and risk factors in Japanese patients with rheumatoid arthritis
    • Sawada T, Inokuma S, Sato T, Otsuka T, Saeki Y, Takeuchi T, et al. Lefl unomide-induced interstitial lung disease:prevalence and risk factors in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(9):1069–72.
    • (2009) Rheumatology (Oxford) , vol.48 , Issue.9 , pp. 1069-1072
    • Sawada, T.1    Inokuma, S.2    Sato, T.3    Otsuka, T.4    Saeki, Y.5    Takeuchi, T.6
  • 9
    • 0026717616 scopus 로고
    • Pharmacological studies of the new antiinfl ammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4’-1-benzopyran-4-o ne. 2nd communication: Eff ect on the arachidonic acid cascades
    • Tanaka K, Makino S, Shimotori T, Aikawa Y, Inaba T, Yoshida C. Pharmacological studies of the new antiinfl ammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4’-1-benzopyran-4-o ne. 2nd communication: eff ect on the arachidonic acid cascades. Arzneimittelforschung. 1992;42(7):945–50.
    • (1992) Arzneimittelforschung , vol.42 , Issue.7 , pp. 945-950
    • Tanaka, K.1    Makino, S.2    Shimotori, T.3    Aikawa, Y.4    Inaba, T.5    Yoshida, C.6
  • 10
    • 0026691789 scopus 로고
    • Pharmacological studies of the new antiinfl ammatory agent  -formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: Anti-infl ammatory, analgesic and other related proper ties
    • Tanaka K, Shimotori T, Makino S, Aikawa Y, Inaba T, Yoshida C, Takano S. Pharmacological studies of the new antiinfl ammatory agent  -formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: anti-infl ammatory, analgesic and other related proper ties. Arzneimittelforschung. 1992; 42(7): 935–44.
    • (1992) Arzneimittelforschung , vol.42 , Issue.7 , pp. 935-944
    • Tanaka, K.1    Shimotori, T.2    Makino, S.3    Aikawa, Y.4    Inaba, T.5    Yoshida, C.6    Takano, S.7
  • 11
    • 0027102875 scopus 로고
    • Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 3rd communication: The involvement of bradykinin in its analgesic actions
    • Tanaka K, Shimotori T, Makino S, Eguchi M, Asaoka K, Kitamura R, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. J Pharmacobiodyn. 1992;15(11):641–7.
    • (1992) J Pharmacobiodyn , vol.15 , Issue.11 , pp. 641-647
    • Tanaka, K.1    Shimotori, T.2    Makino, S.3    Eguchi, M.4    Asaoka, K.5    Kitamura, R.6    Yoshida, C.7
  • 12
    • 0027076809 scopus 로고
    • Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 4th communication: Inhibitory eff ect on the production of interleukin-1 and interleukin-6
    • Tanaka K, Aikawa Y, Kawasaki H, Asaoka K, Inaba T, Yoshida C. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinfl ammatory agent. 4th communication: inhibitory eff ect on the production of interleukin-1 and interleukin-6. J Pharmacobiodyn. 1992; 15(11): 649–55.
    • (1992) J Pharmacobiodyn , vol.15 , Issue.11 , pp. 649-655
    • Tanaka, K.1    Aikawa, Y.2    Kawasaki, H.3    Asaoka, K.4    Inaba, T.5    Yoshida, C.6
  • 13
    • 0033152832 scopus 로고    scopus 로고
    • Inhibitory eff ect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells
    • Kawakami A, Tsuboi M, Urayama S, Matsuoka N, Yamasaki S, Hida A, et al. Inhibitory eff ect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells. J Lab Clin Med. 2012;133(6):566–74.
    • (2012) J Lab Clin Med , vol.133 , Issue.6 , pp. 566-574
    • Kawakami, A.1    Tsuboi, M.2    Urayama, S.3    Matsuoka, N.4    Yamasaki, S.5    Hida, A.6
  • 14
    • 57649112539 scopus 로고    scopus 로고
    • T-614, a novel immunomodulator, attenuates joint infl ammation and articular damage in collagen-induced arthritis
    • Du F, Lü LJ, Fu Q, Dai M, Teng JL, Fan W, et al. T-614, a novel immunomodulator, attenuates joint infl ammation and articular damage in collagen-induced arthritis. Arthritis Res Ther. 2008;10(6):R136.
    • (2008) Arthritis Res Ther , vol.10 , Issue.6 , pp. 136
    • Du, F.1    Lü, L.J.2    Fu, Q.3    Dai, M.4    Teng, J.L.5    Fan, W.6
  • 15
    • 0035204246 scopus 로고    scopus 로고
    • Inhibitory eff ect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells
    • Kohno M, Aikawa Y, Tsubouchi Y, Hashiramoto A, Yamada R, Kawahito Y, et al. Inhibitory eff ect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells. J Rheumatol. 2001;28(12):2591–6.
    • (2001) J Rheumatol , vol.28 , Issue.12 , pp. 2591-2596
    • Kohno, M.1    Aikawa, Y.2    Tsubouchi, Y.3    Hashiramoto, A.4    Yamada, R.5    Kawahito, Y.6
  • 16
    • 84887473612 scopus 로고    scopus 로고
    • A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide
    • Luo Q, Sun Y, Liu W, Qian C, Jin B, Tao F, et al. A novel disease-modifying antirheumatic drug, iguratimod, ameliorates murine arthritis by blocking IL-17 signaling, distinct from methotrexate and leflunomide. J Immunol. 2013;191(10):4969–78.
    • (2013) J Immunol , vol.191 , Issue.10 , pp. 4969-4978
    • Luo, Q.1    Sun, Y.2    Liu, W.3    Qian, C.4    Jin, B.5    Tao, F.6
  • 17
    • 0242609352 scopus 로고    scopus 로고
    • Inhibitory eff ects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice
    • Tanaka K, Yamamoto T, Aikawa Y, Kizawa K, Muramoto K, Matsuno H, et al. Inhibitory eff ects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice. Rheumatology (Oxford). 2003;42(11):1365–71.
    • (2003) Rheumatology (Oxford) , vol.42 , Issue.11 , pp. 1365-1371
    • Tanaka, K.1    Yamamoto, T.2    Aikawa, Y.3    Kizawa, K.4    Muramoto, K.5    Matsuno, H.6
  • 18
    • 0036234632 scopus 로고    scopus 로고
    • An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS-and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation
    • Aikawa Y, Yamamoto M, Yamamoto T, Morimoto K, Tanaka K. An anti-rheumatic agent T-614 inhibits NF-kappaB activation in LPS-and TNF-alpha-stimulated THP-1 cells without interfering with IkappaBalpha degradation. Inflamm Res. 2002;51(4):188–94.
    • (2002) Inflamm Res , vol.51 , Issue.4 , pp. 188-194
    • Aikawa, Y.1    Yamamoto, M.2    Yamamoto, T.3    Morimoto, K.4    Tanaka, K.5
  • 19
    • 0027489894 scopus 로고
    • Pharmacological studies of T-614, a novel antiinfl ammaory agent. Eff ect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice
    • Tanaka K, Shimotori T, Taniguchi Y, Eguchi M, A be C. Pharmacological studies of T-614, a novel antiinfl ammaory agent. Eff ect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/l mice. Int J Immunother. 1993;9:69–78.
    • (1993) Int J Immunother , vol.9 , pp. 69-78
    • Tanaka, K.1    Shimotori, T.2    Taniguchi, Y.3    Eguchi, M.4    A Be, C.5
  • 20
    • 34247593508 scopus 로고    scopus 로고
    • Effi cacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: A controlled, multicenter, double-blind, parallel-group study
    • Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, et al. Effi cacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. Mod Rheumatol. 2007;17(1):1–9.
    • (2007) Mod Rheumatol , vol.17 , Issue.1 , pp. 1-9
    • Hara, M.1    Abe, T.2    Sugawara, S.3    Mizushima, Y.4    Hoshi, K.5    Irimajiri, S.6
  • 21
    • 84900384454 scopus 로고    scopus 로고
    • Safety and effi cacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial
    • Hara M, Ishiguro N, Katayama K, Kondo M, Sumida T, Mimori T, et al. Safety and effi cacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: An open-label extension of a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2014;24(3):410–8.
    • (2014) Mod Rheumatol , vol.24 , Issue.3 , pp. 410-418
    • Hara, M.1    Ishiguro, N.2    Katayama, K.3    Kondo, M.4    Sumida, T.5    Mimori, T.6
  • 22
    • 84877732792 scopus 로고    scopus 로고
    • Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: A randomized, double-blind, placebo-controlled trial
    • Ishiguro N, Yamamoto K, Katayama K, Kondo M, Sumida T, Mimori T, et al. Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Mod Rheumatol. 2013;23(3):430–9.
    • (2013) Mod Rheumatol , vol.23 , Issue.3 , pp. 430-439
    • Ishiguro, N.1    Yamamoto, K.2    Katayama, K.3    Kondo, M.4    Sumida, T.5    Mimori, T.6
  • 23
    • 46449101583 scopus 로고    scopus 로고
    • Safety and effi cacy of T-614 in the treatment of patients with active rheumatoid arthritis: A double blind, randomized, placebo-controlled and multicenter trial
    • Lü LJ, Teng JL, Bao CD, Han XH, Sun LY, Xu JH, et al. Safety and effi cacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial. Chin Med J (Engl). 2008;121(7):615–9.
    • (2008) Chin Med J (Engl) , vol.121 , Issue.7 , pp. 615-619
    • Lü, L.J.1    Teng, J.L.2    Bao, C.D.3    Han, X.H.4    Sun, L.Y.5    Xu, J.H.6
  • 24
    • 67650470192 scopus 로고    scopus 로고
    • Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate
    • Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. Arthritis Rheum. 2008;61(7):979–87.
    • (2008) Arthritis Rheum , vol.61 , Issue.7 , pp. 979-987
    • Lu, L.J.1    Bao, C.D.2    Dai, M.3    Teng, J.L.4    Fan, W.5    Du, F.6
  • 25
    • 84893735702 scopus 로고    scopus 로고
    • Effi cacy and safety of iguratimod for the treatment of rheumatoid arthritis
    • Li J, Mao H, Liang Y, Lu Y, Chen S, Yang N, Shi G. Effi cacy and safety of iguratimod for the treatment of rheumatoid arthritis. Clin Dev Immunol. 2013;2013:310628.
    • (2013) Clin Dev Immunol , vol.2013 , pp. 310628
    • Li, J.1    Mao, H.2    Liang, Y.3    Lu, Y.4    Chen, S.5    Yang, N.6    Shi, G.7
  • 26
    • 84868636363 scopus 로고    scopus 로고
    • Iguratimod: A new disease-modifying antirheumatic drug
    • Mucke HA. Iguratimod: a new disease-modifying antirheumatic drug. Drugs Today (Barc). 2012;48(9):577–86.
    • (2012) Drugs Today (Barc) , vol.48 , Issue.9 , pp. 577-586
    • Mucke, H.A.1
  • 27
    • 85022130305 scopus 로고    scopus 로고
    • Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis
    • Okamura K, Yonemoto Y, Okura C, Kobayashi T, Takagishi T. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis. Mod Rheumatol. 2014;28:1–6.
    • (2014) Mod Rheumatol , vol.28 , pp. 1-6
    • Okamura, K.1    Yonemoto, Y.2    Okura, C.3    Kobayashi, T.4    Takagishi, T.5
  • 28
    • 0023945481 scopus 로고    scopus 로고
    • The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis
    • Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classifi cation of rheumatoid arthritis. Arthritis Rheum. 1998;31(3):315–24.
    • (1998) Arthritis Rheum , vol.31 , Issue.3 , pp. 315-324
    • Arnett, F.C.1    Edworthy, S.M.2    Bloch, D.A.3    Mcshane, D.J.4    Fries, J.F.5    Cooper, N.S.6
  • 30
    • 20444481876 scopus 로고    scopus 로고
    • Treatment continuation in patients receiving biological agents or conventional DMARD therapy
    • Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. Ann Rheum Dis. 2005;64(9):1274–9.
    • (2005) Ann Rheum Dis , vol.64 , Issue.9 , pp. 1274-1279
    • Zink, A.1    Listing, J.2    Kary, S.3    Ramlau, P.4    Stoyanova-Scholz, M.5    Babinsky, K.6
  • 31
    • 0141427819 scopus 로고    scopus 로고
    • Survival and eff ectiveness of lefl unomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: A matched observational study
    • Aletaha D, Stamm T, Kapral T, Eberl G, Grisar J, Machold KP, et al. Survival and eff ectiveness of lefl unomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis. 2003;62(10):944–51.
    • (2003) Ann Rheum Dis , vol.62 , Issue.10 , pp. 944-951
    • Aletaha, D.1    Stamm, T.2    Kapral, T.3    Eberl, G.4    Grisar, J.5    Machold, K.P.6
  • 33
    • 84859153165 scopus 로고    scopus 로고
    • T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fi broblasts, in vitro
    • Du F, Lü LJ, Teng JL, Shen N, Ye P, Bao CD. T-614 alters the production of matrix metalloproteinases (MMP-1 and MMP-3) and inhibits the migratory expansion of rheumatoid synovial fi broblasts, in vitro. Int Immunopharmacol. 2012;13(1):54–60.
    • (2012) Int Immunopharmacol , vol.13 , Issue.1 , pp. 54-60
    • Du, F.1    Lü, L.J.2    Teng, J.L.3    Shen, N.4    Ye, P.5    Bao, C.D.6
  • 34
    • 0029016804 scopus 로고
    • T-614 a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts
    • Tanaka K, Kawasaki H, Kurata K, Aikawa Y, Tsukamoto Y, Inaba T. T-614 a novel antirheumatic drug, inhibits both the activity and induction of cyclooxygenase-2 (COX-2) in cultured fibroblasts. Jpn J Pharmacol. 1995;67(4):305–14.
    • (1995) Jpn J Pharmacol , vol.67 , Issue.4 , pp. 305-314
    • Tanaka, K.1    Kawasaki, H.2    Kurata, K.3    Aikawa, Y.4    Tsukamoto, Y.5    Inaba, T.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.